drugset / Trial / NCT02666105
Exemestane in Post-Menopausal Women With NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
Timeline
- Start
- 2018-09-27
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | — |